We demonstrate substantial improvements by incorporating markers of the tumor microenvironment, specifically stromal FOXC1 and tumor pERK1‐2 expressions, offering a multidimensional approach to DLBCL prognosis. Here, FOXC1 is linked to diffuse large B-cell lymphoma.